A Phase 2 Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma

Phase 2 Not yet recruiting 512 enrolled Kinaset Therapeutics Inc

RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) Over a 12-Week Treatment Period in Patients With Severe Asthma Not Controlled With Medium to High Dose ICS/LABA

Timeline

Start: 2026-06-01
Primary completion: 2027-11-30
Completion: 2027-11-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Frevecitinib	Small molecule	—	Inhaled

A Phase 2 Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma

Summary

Timeline

Drugs

Indications